51 related articles for article (PubMed ID: 37378567)
21. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
22. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
[TBL] [Abstract][Full Text] [Related]
23. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.
Pósfai É; Marton I; Király PA; Kotosz B; Kiss-László Z; Széll M; Borbényi Z
Pathol Oncol Res; 2015 Jul; 21(3):751-8. PubMed ID: 25573593
[TBL] [Abstract][Full Text] [Related]
24. Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
Sun C; Zhou X; Zou ZJ; Guo HF; Li JY; Qiao C
Chin Med J (Engl); 2016 Aug; 129(15):1778-83. PubMed ID: 27453224
[TBL] [Abstract][Full Text] [Related]
25. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
26.
Furuya C; Hashimoto Y; Morishita S; Inano T; Ochiai T; Shirane S; Edahiro Y; Araki M; Ando M; Komatsu N
Hematology; 2023 Dec; 28(1):2229131. PubMed ID: 37378567
[TBL] [Abstract][Full Text] [Related]
27. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
Barbui T; Falanga A
Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
[TBL] [Abstract][Full Text] [Related]
28. Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations.
Wang J; Fu W; Bao W; Gong W; Xu S; Ling C; Jin Q; Zhang Q
Platelets; 2023 Dec; 34(1):2176167. PubMed ID: 36786035
[TBL] [Abstract][Full Text] [Related]
29. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
30. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
31. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
32. It is time to change thrombosis risk assessment for PV and ET?
Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
[TBL] [Abstract][Full Text] [Related]
33. Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.
Falchi L; Kantarjian HM; Verstovsek S
Leukemia; 2017 Sep; 31(9):1845-1854. PubMed ID: 28529308
[TBL] [Abstract][Full Text] [Related]
34. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
Ben Said M; Gandrille S; Fischer AM; Darnige L
Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]